GlassScriptPhysician profile
Kimberly Sumner Messina
NPI 1225702871
$8,857.07
in general payments reported to CMS, 2019-2025
29 companies · $2,219 in 2025
The $2,219 reported for 2025 was more than what 92% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $2,517 · 2023: $2,218 · 2024: $1,903 · 2025: $2,219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,056 · Education: $284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,056.24 |
| Education | $283.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,382.69 | 2022-2025 | |
| Genzyme Corporation | $1,074.45 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,030.93 | 2022-2025 | Sotyktu |
| Amgen INC. | $666.67 | 2022-2024 | Otezla |
| Janssen Biotech, INC. | $656.32 | 2022-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $630.68 | 2023-2025 | |
| Ucb, INC. | $499.84 | 2023-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $471.19 | 2022-2025 | Dupixent, Libtayo |
| Incyte Corporation | $345.36 | 2022-2024 | Opzelura |
| Lilly USA, LLC | $327.87 | 2022-2025 | Ebglyss, Taltz |
| Arcutis Biotherapeutics, INC. | $305.93 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $292.35 | 2022-2025 | Ilumya |
| Galderma Laboratories, L.P. | $272.06 | 2025 | Nemluvio, Aklief |
| Pfizer INC. | $252.78 | 2022-2025 | |
| Organon LLC | $141.01 | 2025 | Vtama |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $118.31 | 2023-2025 | Adbry, Anzupgo |
| Epi Health, LLC | $73.66 | 2022 | |
| Dermavant Sciences, INC. | $46.14 | 2023-2024 | Vtama |
| Journey Medical Corporation | $43.73 | 2022-2025 | |
| Abiomed | $43.51 | 2024 | Impella |
| Cipher Pharmaceuticals US LLC | $29.07 | 2025 | Natroba, Spinosad |
| Almirall LLC | $23.74 | 2022 | |
| Verrica Pharmaceuticals INC. | $22.44 | 2023 | Ycanth |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.88 | 2022 | |
| Biofrontera INC. | $20.59 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $19.10 | 2024 | Cabtreo |
| Sandoz INC. | $17.41 | 2024 | Hyrimoz |
| Botanix Sb INC | $14.83 | 2025 | Sofdra |
| Mission Pharmacal Company | $13.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Messina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.